Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
LDP Panel Backs Support for Drug Wholesalers in Economic Package
The Liberal Democratic Party’s (LDP) Health, Labor and Welfare Division has formally written support measures for pharmaceutical wholesalers into its list of priority items for the party’s upcoming economic package, due to be hammered out later this month. The list,…
To read the full story
Related Article
- Japan Finalizes Economic Package Positioning Pharma as “Core Industry”
November 25, 2025
- Health Minister Says Govt Mulling Backing for Wholesaler Support
November 13, 2025
- LDP Project Team Urges Economic Measures Reflecting Price Pressures
November 4, 2025
- LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
- Makoto Oniki Tapped as Head of LDP’s Health Division
October 27, 2025
REGULATORY
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
- Japan OKs 2nd OTC Emergency Contraceptive, Launch Set for March 9
February 12, 2026
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…